Premium
Treatment of two cases with refractory, metastatic intermediate‐risk neuroblastoma with isotretenoin alone or observation
Author(s) -
Pinto Navin,
Cipkala Douglas A.,
Ladd Patricia E.,
Pu Yonglin,
Cohn Susan L.
Publication year - 2014
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24889
Subject(s) - neuroblastoma , medicine , refractory (planetary science) , isotretinoin , chemotherapy , oncology , disease , stage (stratigraphy) , minimal residual disease , leukemia , dermatology , biology , paleontology , astrobiology , acne , cell culture , genetics
Patients <12 months with favorable biology, metastatic neuroblastoma have >90% overall survival following treatment with chemotherapy and surgery. We report two infants with favorable biology, stage 4 neuroblastoma with refractory disease after standard intermediate‐risk chemotherapy and additional retrieval chemotherapy. One patient was treated with six additional cycles of isotretinoin and the other observed. Both remain clinically well with persistent disease but no evidence of tumor progression for 28 and 13 months following completion of cytotoxic treatment. Similar to residual tumor in primary sites, refractory metastatic disease may not portend a poor outcome in patients with favorable biology, intermediate‐risk neuroblastoma. Pediatr Blood Cancer 2014;61:1104–1106. © 2013 Wiley Periodicals, Inc.